BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26542540)

  • 1. Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas.
    Liu Y; Hu H; Zhang C; Wang Z; Li M; Jiang T
    Genes Chromosomes Cancer; 2016 Feb; 55(2):169-76. PubMed ID: 26542540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
    Gladitz J; Klink B; Seifert M
    Acta Neuropathol Commun; 2018 Jun; 6(1):49. PubMed ID: 29890994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
    Sathornsumetee S; Cheunsuchon P; Sangruchi T
    World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status.
    Katsetos CD; Del Valle L; Geddes JF; Aldape K; Boyd JC; Legido A; Khalili K; Perentes E; Mörk SJ
    J Neuropathol Exp Neurol; 2002 Apr; 61(4):307-20. PubMed ID: 11939586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
    Tews B; Felsberg J; Hartmann C; Kunitz A; Hahn M; Toedt G; Neben K; Hummerich L; von Deimling A; Reifenberger G; Lichter P
    Int J Cancer; 2006 Aug; 119(4):792-800. PubMed ID: 16550607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
    Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
    Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
    Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
    Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
    Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy.
    Pandith AA; Zahoor W; Manzoor U; Nisar S; Guru FR; Naikoo NA; Aein QU; Baba SM; Bhat AR; Ganai F; Shah P
    Cancer Genet; 2023 Nov; 278-279():55-61. PubMed ID: 37625215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
    Snuderl M; Eichler AF; Ligon KL; Vu QU; Silver M; Betensky RA; Ligon AH; Wen PY; Louis DN; Iafrate AJ
    Clin Cancer Res; 2009 Oct; 15(20):6430-7. PubMed ID: 19808867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM; Lesniak MS
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
    J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
    Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
    Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.